| 摘要 |
A monoclonal antibody (FE8) against human complement receptor type 2 CR2, CD21) which is able to substantially remove C3-derived fragments already attached to CR2, in particular C3dg from CR2 at temperatures of 25� C. and above. Furthermore, the invention covers hybridoma cells and processes to obtain antibodies, as well as therapeutic applications. |
